ストックスクリーナーアプリを入手
1.76
5.88%
-0.11
アフターアワーズ：
1.75
-0.01
-0.57%
Cadrenal Therapeutics Inc (CVKD) 最新ニュース
Avoiding Lag: Real-Time Signals in (CVKD) Movement - Stock Traders Daily
Cadrenal Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cadrenal Maintained at Buy as Partnership-Focused Strategy Supports Unchanged $13 Price Target - TipRanks
PNC Financial Services Group, Inc. Acquires New Stake in Cadrenal Therapeutics Inc (CVKD) - GuruFocus
Cadrenal Therapeutics Q2 Results: Net Loss Narrows To $3.3 Million - scanx.trade
Cadrenal Therapeutics reports Q2 2026 net loss of $3.3M; cash runway into Q1 2027 - TradingView
Cadrenal CAD-1005 data show more than 25% absolute drop in clot events - Stock Titan
Cadrenal Therapeutics Inc (CVKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a shareEarnings Preview - TradingView
Cadrenal Therapeutics (CVKD): PNC discloses 8.13% beneficial stake for client - Stock Titan
CVKD | Cadrenal Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Cadrenal Therapeutics (CVKD) Slips 2.49% to $1.96 as Shares Test Range-Bound SupportAI Trade Signals - dars.gov.et
CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy - Smartkarma
Cadrenal expands CAD-1005 development to two indications - Investing.com
Cadrenal expands CAD-1005 development to two indications By Investing.com - Investing.com India
Cadrenal Therapeutics Highlights CAD-1005 as Dual-Indication 12-LOX Inhibitor for HIT and CSA-AKI Following Competing Trial Failure - Quiver Quantitative
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation - Yahoo Finance
Cadrenal Therapeutics (CVKD) Drops 3.8%, Approaches Critical $1.91 SupportSentiment Divergence - dars.gov.et
Cadrenal Therapeutics Inc (CVKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cadrenal Therapeutics Inc (CVKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cadrenal Therapeutics Inc (CVKD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CVKD|Cadrenal Therapeutics Inc|Price:1.830|Chg%:-0.030 - TradingKey
Cadrenal Therapeutics Inc (CVKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cadrenal Therapeutics Inc (CVKD) Institutional Confidence - TradingKey
Cadrenal Therapeutics Inc (CVKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CVKD|Cadrenal Therapeutics Inc|Price:2.045|Chg%:-0.015 - TradingKey
Cadrenal Therapeutics Inc (CVKD) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
TradingKey - TradingKey
Cadrenal Therapeutics Inc (CVKD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cadrenal Therapeutics Market Sentiment - Benzinga España
Cadrenal Therapeutics, Inc. Revenue Breakdown – NASDAQ:CVKD - TradingView
CVKD|Cadrenal Therapeutics Inc|Price:2.030|Chg%:-0.010 - TradingKey
Form PRE 14A CADRENAL THERAPEUTICS For: 23 July By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (NASDAQ: CVKD) seeks approval for 1M-share equity plan and 960K warrant shares - Stock Titan
H.C. Wainwright Maintains Cadrenal Therapeutics(CVKD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cadrenal seeks partners for cardiac care drug portfolio By Investing.com - Investing.com South Africa
Cadrenal Therapeutics, Inc. SEC Filing (Jul 21, 2026) - Stock Titan
Cadrenal Therapeutics Launches Cardiac Acute Care Franchise Strategy - TipRanks
Cadrenal seeks partners for cardiac care drug portfolio - Investing.com
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation - The Manila Times
Cadrenal Therapeutics Launches Partnering Process as Its - GlobeNewswire
Cadrenal Therapeutics Announces Chief Medical Officer Transition - The Globe and Mail
Cadrenal Therapeutics (NASDAQ: CVKD) outlines CMO Ferguson's exit deal - Stock Titan
Cadrenal Therapeutics (CVKD) Edges Lower Amid Mixed Sentiment, Holding Above Key SupportBollinger Expansion - po-news-eg.net
Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing - Stock Titan
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
CADRENAL THERAPEUTICSNO SERIOUS ADVERSE EVENTS OR DEATHS REPORTED WITH CAD-1005 IN PHASE 2 TRIAL - webull.com
Form S-3 Cadrenal Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (NASDAQ: CVKD) files resale for 2.94M warrant shares - Stock Titan
Cadrenal presents phase 2 data for CAD-1005 at ISTH congress - Investing.com Nigeria
Cadrenal presents phase 2 data for CAD-1005 at ISTH congress By Investing.com - Investing.com South Africa
Cadrenal Therapeutics Presents Positive Phase 2 CAD-1005 Data in Late-Breaking ISTH Oral Presentation for Heparin-Induced Thrombocytopenia - Quiver Quantitative
Experimental CAD-1005 drug cuts serious blood clots in HIT patients by over 25% - Stock Titan
Cadrenal's CAD-1005 cuts thrombotic events by over 25% in Phase 2 - scanx.trade
symbol__ Stock Quote Price and Forecast - CNN
Cadrenal Therapeutics Announces Chief Medical Officer Resignation - theglobeandmail.com
Cadrenal Therapeutics (CVKD) Chief Medical Officer James Ferguson to step down July 31, 2026 - Stock Titan
Cadrenal Therapeutics, Inc. Announces Resignation of James J. Ferguson III from Chief Medical Officer Role, Effective July 31, 2026 - marketscreener.com
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):